UBS Group
ALGS icon

UBS Group’s Aligos Therapeutics ALGS Stock Holding History

UBS Group’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Buy
59,986
+22,925
+62% +$142K ﹤0.01% 6459
2026
Q1 		$275K Buy
37,061
+36,697
+10,082% +$278K ﹤0.01% 6452
2025
Q4 		$3.39K Sell
364
-15,818
-98% -$149K ﹤0.01% 9034
2025
Q3 		$159K Buy
16,182
+13,439
+490% +$123K ﹤0.01% 6803
2025
Q2 		$19.8K Sell
2,743
-5,718
-68% -$34.2K ﹤0.01% 8452
2025
Q1 		$69.8K Sell
8,461
-7,060
-45% -$155K ﹤0.01% 7330
2024
Q4 		$618K Buy
15,521
+15,507
+110,764% +$300K ﹤0.01% 5694
2024
Q3 		$121 Hold
14
– – ﹤0.01% 9139
2024
Q2 		$127 Sell
14
-419
-97% -$7.37K ﹤0.01% 9128
2024
Q1 		$10.6K Buy
+433
New +$8.62K ﹤0.01% 7217
2023
Q4 		– Sell
-217
Closed -$4.06K – 9255
2023
Q3 		$4.06K Buy
217
+212
+4,240% +$4.7K ﹤0.01% 7481
2023
Q2 		$110 Sell
5
-88
-95% -$2.36K ﹤0.01% 8490
2023
Q1 		$2.04K Buy
+93
New +$3.55K ﹤0.01% 8600
2022
Q1 		– Sell
-302
Closed -$90K – 10188
2021
Q4 		$90K Buy
302
+273
+941% +$99.6K ﹤0.01% 6401
2021
Q3 		$11K Buy
29
+15
+107% +$5.93K ﹤0.01% 7858
2021
Q2 		$7K Sell
14
-131
-90% -$83.5K ﹤0.01% 8307
2021
Q1 		$83K Buy
145
+78
+116% +$51.9K ﹤0.01% 6104
2020
Q4 		$46K Buy
+67
New +$32.6K ﹤0.01% 6256

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's ALGS Position: Q2 2026 in Review

UBS Group increased its Aligos Therapeutics (ALGS) stake by 62% in Q2 2026, buying an estimated $142K and bringing the position to 59,986 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #6459.

UBS Group first reported a position in ALGS in Q4 2020 and has held it in 18 quarters since. The position peaked at $618K in Q4 2024. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • UBS Group held 59,986 shares of Aligos Therapeutics worth $346K as of Q2 2026.
  • UBS Group bought 22,925 Aligos Therapeutics shares in Q2 2026, an estimated $142K.
  • Aligos Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6459 holding.
  • UBS Group first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 18 quarters since.
  • UBS Group's Aligos Therapeutics position peaked at $618K in Q4 2024.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.